Lixudebart is under clinical development by Alentis Therapeutics and currently in Phase II for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis). According to GlobalData, Phase II drugs for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Lixudebart’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lixudebart overview
ALEF-02 is under development for the treatment of liver, kidney, pulmonary fibrosis (lung fibrosis), anti-neutrophil cytoplasmic antibody-associated vasculitis (ANCA vasculitis). It acts by targeting a claudin 1 (CLDN1). It is administered by intravenous route.
It was also under development for the treatment of solid tumors.
Alentis Therapeutics overview
Alentis Therapeutics (Alentis) is biotech company that develops treatments for fibrotic disease and associated cancer. The company addresses the unmet medical needs of patients through the development of medication based on the discovery of the CLDN-1 Protien. the companie’s pipeline portfolio includes: ALE.C04, It has been developed to directly target the cancer while scilencing the CLDN1-mediated carcinogenic signaling and opening up the stiff extracellular matrix (ECM) in tumors with immune evasive properties. ALE.F02, has been developed with a silenced effector function to target the stiff ECM of fibrotic tissues and organs, which also under development for kidney, lung, and liver fibrosis. Alentis is headquartered in Basel, Switzerland.
For a complete picture of Lixudebart’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
